Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 70 articles:
HTML format



Single Articles


    September 2021
  1. PORCIUNCULA A, Morgado M, Gupta R, Syrigos K, et al
    Spatial mapping and immunomodulatory role of the OX40/OX40L pathway in human non-small cell lung cancer.
    Clin Cancer Res. 2021 Sep 13. pii: 1078-0432.CCR-21-0987.
    PubMed     Abstract available


    August 2021
  2. SHI J, Wang Z, Zhang J, Xu Y, et al
    Genomic landscape and tumor mutational burden determination of circulating tumor DNA in over 5,000 Chinese lung cancer patients.
    Clin Cancer Res. 2021 Aug 26. pii: 1078-0432.CCR-21-1537.
    PubMed     Abstract available


  3. CAMIDGE DR, Morgensztern D, Heist RS, Barve M, et al
    Phase 1 Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients With Advanced Non-Small Cell Lung Carcinoma.
    Clin Cancer Res. 2021 Aug 23. pii: 1078-0432.CCR-21-0765.
    PubMed     Abstract available


  4. SUZUKI S, Yonesaka K, Teramura T, Takehara T, et al
    KRAS inhibitor-resistance in MET-amplified KRAS (G12C) non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms.
    Clin Cancer Res. 2021 Aug 7. pii: 1078-0432.CCR-21-0856.
    PubMed     Abstract available


    July 2021
  5. NAKAGAWA K, Nadal E, Garon EB, Nishio M, et al
    RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-small Cell Lung Cancer.
    Clin Cancer Res. 2021 Jul 22. pii: 1078-0432.CCR-21-0273.
    PubMed     Abstract available


  6. KOCH AL, Vellanki PJ, Drezner N, Li X, et al
    FDA Approval Summary: Osimertinib for adjuvant treatment of surgically resected non-small cell lung cancer, a collaborative Project Orbis review.
    Clin Cancer Res. 2021 Jul 22. pii: 1078-0432.CCR-21-1034.
    PubMed     Abstract available


  7. LUO J, Martucci VL, Quandt Z, Groha S, et al
    Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer.
    Clin Cancer Res. 2021 Jul 8. pii: 1078-0432.CCR-21-0921.
    PubMed     Abstract available


    June 2021
  8. WEISS SA, Djureinovic D, Jessel S, Krykbaeva I, et al
    A phase I study of APX005M and cabiralizumab with/without nivolumab in patients with melanoma, kidney cancer or non-small cell lung cancer resistant to anti-PD-(L)1.
    Clin Cancer Res. 2021 Jun 17. pii: 1078-0432.CCR-21-0903.
    PubMed     Abstract available


  9. GARON EB, Spira AI, Johnson M, Bazhenova L, et al
    A phase 1b open-label, multicenter study of inhaled DV281, a TLR9 agonist, in combination with nivolumab in patients with advanced or metastatic non-small cell lung cancer.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-0263.
    PubMed     Abstract available


    May 2021
  10. CORTOT AB, Madroszyk-Flandin A, Giroux Leprieur E, Molinier O, et al
    First-line Afatinib plus Cetuximab for EGFR-mutant Non-small-cell Lung Cancer: Results from the Randomized Phase 2 IFCT-1503 ACE-Lung Study.
    Clin Cancer Res. 2021 May 24. pii: 1078-0432.CCR-20-4604.
    PubMed     Abstract available


  11. BYERS LA, Bentsion D, Gans S, Penkov K, et al
    Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naive Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
    Clin Cancer Res. 2021 May 4. pii: 1078-0432.CCR-20-4259.
    PubMed     Abstract available


    April 2021
  12. SHAFIQUE M, Fisher TL, Evans EE, Leonard JE, et al
    A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Apr 5. pii: 1078-0432.CCR-20-4792.
    PubMed     Abstract available


    March 2021
  13. LIN JJ, Choudhury NJ, Yoda S, Zhu VW, et al
    Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
    Clin Cancer Res. 2021 Mar 8. pii: 1078-0432.CCR-21-0032.
    PubMed     Abstract available


  14. AGGARWAL C, Thompson JC, Carpenter EL
    Plasma Tumor Mutation Burden and Response to Pembrolizumab-Response.
    Clin Cancer Res. 2021;27:1581.
    PubMed    


  15. XUE Z, Guo X, Wen J, Cai W, et al
    Plasma Tumor Mutation Burden and Response to Pembrolizumab-Letter.
    Clin Cancer Res. 2021;27:1580.
    PubMed    


    February 2021
  16. VELLANKI PJ, Mulkey F, Jaigirdar AA, Rodriguez L, et al
    FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review.
    Clin Cancer Res. 2021 Feb 25. pii: 1078-0432.CCR-20-4338.
    PubMed     Abstract available


  17. DATAR IJ, Hauc S, Desai SS, Gianino N, et al
    Spatial analysis and clinical significance of HLA class-I and class-II subunit expression in non-small cell lung cancer.
    Clin Cancer Res. 2021 Feb 18. pii: 1078-0432.CCR-20-3655.
    PubMed     Abstract available


  18. SKWARSKI M, McGowan DR, Belcher E, Di Chiara F, et al
    Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Feb 17. pii: 1078-0432.CCR-20-4128.
    PubMed     Abstract available


  19. GARON EB
    Osimertinib plus Ramucirumab: The Best of Both Worlds?
    Clin Cancer Res. 2021;27:905-907.
    PubMed     Abstract available


  20. SKOULIDIS F
    Transcription Strikes Back: Clinical Utility of Lung Adenocarcinoma Subtypes.
    Clin Cancer Res. 2021;27:913-915.
    PubMed     Abstract available


  21. HARVEY RD, Bruinooge SS, Chen L, Garrett-Mayer E, et al
    Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations.
    Clin Cancer Res. 2021 Feb 9. pii: 1078-0432.CCR-20-3857.
    PubMed     Abstract available


  22. ARBOUR KC, Rizvi H, Plodkowski AJ, Hellmann MD, et al
    Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C Mutant Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Feb 8. pii: 1078-0432.CCR-20-4023.
    PubMed     Abstract available


    January 2021
  23. DEUTSCH E, Chargari C, Weichselbaum RR, Levy A, et al
    Drug-Radiotherapy Combination Trial Developments-Response.
    Clin Cancer Res. 2021;27:356.
    PubMed    


  24. EVANS JR, Cuneo KC, Lawrence TS
    Drug-Radiotherapy Combination Trial Developments-Letter.
    Clin Cancer Res. 2021;27:355.
    PubMed    


    December 2020
  25. SINGH S, Jaigirdar AA, Mulkey F, Cheng J, et al
    FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer.
    Clin Cancer Res. 2020 Dec 7. pii: 1078-0432.CCR-20-3901.
    PubMed     Abstract available


  26. DE HAAN R, Van den Heuvel M, van Diessen J, Peulen HMU, et al
    Phase 1 and pharmacological study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer.
    Clin Cancer Res. 2020 Dec 1. pii: 1078-0432.CCR-20-2551.
    PubMed     Abstract available


    November 2020
  27. GIFFIN MJ, Cooke K, Lobenhofer EK, Estrada JC, et al
    AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small Cell Lung Cancer.
    Clin Cancer Res. 2020 Nov 17. pii: 1078-0432.CCR-20-2845.
    PubMed     Abstract available


  28. SALAS-BENITO D, Eguren-Santamaria I, Sanmamed MF
    Senescent T-cells as a resistance mechanism to lung cancer immunotherapy.
    Clin Cancer Res. 2020 Nov 13. pii: 1078-0432.CCR-20-3507.
    PubMed     Abstract available


    October 2020
  29. ROSEN EY, Johnson ML, Clifford SE, Somwar R, et al
    Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib.
    Clin Cancer Res. 2020 Oct 20. pii: 1078-0432.CCR-20-2278.
    PubMed     Abstract available


  30. SINGH A, Daemen A, Nickles D, Jeon SM, et al
    NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes.
    Clin Cancer Res. 2020 Oct 19. pii: 1078-0432.CCR-20-1985.
    PubMed     Abstract available


  31. YU HA, Paz-Ares LG, Yang JC, Lee KH, et al
    Phase 1 Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2020 Oct 12. pii: 1078-0432.CCR-20-1690.
    PubMed     Abstract available


    September 2020
  32. ADACHI Y, Ito K, Hayashi Y, Kimura R, et al
    Epithelial to mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant non-small cell lung cancer.
    Clin Cancer Res. 2020 Sep 8. pii: 1078-0432.CCR-20-2077.
    PubMed     Abstract available


  33. FERRARA R, Naigeon M, Auclin E, Duchemann B, et al
    Circulating T-cell immunosenescence in advanced non-small cell lung cancer patients treated with single agent PD-1/PD-L1 inhibitors or platinum-based chemotherapy.
    Clin Cancer Res. 2020 Sep 4. pii: 1078-0432.CCR-20-1420.
    PubMed     Abstract available


    August 2020
  34. ORTIZ-CUARAN S, Mezquita L, Swalduz A, Aldea M, et al
    Circulating tumor DNA genomics reveals potential mechanisms of resistance to BRAF-targeted therapies in BRAF-mutant metastatic non-small cell lung cancer patients.
    Clin Cancer Res. 2020 Aug 28. pii: 1078-0432.CCR-20-1037.
    PubMed     Abstract available


  35. GERBER DE, Putnam WC, Fattah FJ, Kernstine KH, et al
    Concentration-dependent early anti-vascular and anti-tumor effects of itraconazole in non-small cell lung cancer.
    Clin Cancer Res. 2020 Aug 26. pii: 1078-0432.CCR-20-1916.
    PubMed     Abstract available


  36. XING L, Pan Y, Shi Y, Shu Y, et al
    Biomarkers of osimertinib response in patients with refractory, EGFR-T790M-positive non-small cell lung cancer and central nervous system metastases:the APOLLO study.
    Clin Cancer Res. 2020 Aug 17. pii: 1078-0432.CCR-20-2081.
    PubMed     Abstract available


    July 2020
  37. MADAJEWSKI B, Chen F, Yoo B, Turker MZ, et al
    Molecular Engineering of Ultrasmall Silica Nanoparticle-Drug Conjugates as Lung Cancer Therapeutics.
    Clin Cancer Res. 2020 Jul 28. pii: 1078-0432.CCR-20-0851.
    PubMed     Abstract available


  38. SCHOENFELD AJ, Bandlamudi C, Lavery JA, Montecalvo J, et al
    The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer.
    Clin Cancer Res. 2020 Jul 24. pii: 1078-0432.CCR-20-1825.
    PubMed     Abstract available


  39. BLAKELY CM, McCoach CE
    Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies.
    Clin Cancer Res. 2020;26:3499-3500.
    PubMed     Abstract available


  40. MULLER M, Hummelink K, Hurkmans DP, Niemeijer AN, et al
    A serum protein classifier identifying patients with advanced non-small cell lung cancer who derive clinical benefit from treatment with immune checkpoint inhibitors.
    Clin Cancer Res. 2020 Jul 6. pii: 1078-0432.CCR-20-0538.
    PubMed     Abstract available


  41. AGGARWAL C, Thompson JC, Carpenter EL
    Plasma Tumor Mutation Burden and Response to Pembrolizumab-Response.
    Clin Cancer Res. 2020;26:3492.
    PubMed    


  42. LI X, Xu Y, Wang G, Li L, et al
    Plasma Tumor Mutation Burden and Response to Pembrolizumab-Letter.
    Clin Cancer Res. 2020;26:3491.
    PubMed    


  43. GOERIG NL, Frey B, Korn K, Fleckenstein B, et al
    Early Mortality of Brain Cancer Patients and its Connection to Cytomegalovirus Reactivation During Radiochemotherapy.
    Clin Cancer Res. 2020;26:3259-3270.
    PubMed     Abstract available


    June 2020
  44. HIPP S, Voynov V, Drobits-Handl B, Giragossian C, et al
    A Bispecific DLL3/CD3 IgG-like T-cell Antibody induces anti-tumor responses in Small Cell Lung Cancer.
    Clin Cancer Res. 2020 Jun 18. pii: 1078-0432.CCR-20-0926.
    PubMed     Abstract available


  45. VAN DEN BROECK A, Brambilla E, Moro-Sibilot D, Lantuejoul S, et al
    Correction: Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2020;26:2768.
    PubMed    


  46. VAN DEN BROECK A, Brambilla E, Moro-Sibilot D, Lantuejoul S, et al
    Correction: Editor's Note: Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2020;26:2767.
    PubMed    


  47. PIOTROWSKA Z, Hata AN
    Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue.
    Clin Cancer Res. 2020;26:2441-2443.
    PubMed     Abstract available


    May 2020
  48. LIU B, Ricarte-Filho J, Mallisetty A, Villani C, et al
    Detection of promoter DNA methylation in urine and plasma aids the detection of non-small cell lung cancer.
    Clin Cancer Res. 2020 May 19. pii: 1078-0432.CCR-19-2896.
    PubMed     Abstract available


  49. BAGLEY SJ, Carpenter EL
    Plasma cfDNA in Glioblastoma-Response.
    Clin Cancer Res. 2020;26:2276.
    PubMed    


  50. GLITZA OLIVA IC, Tawbi HA
    "Liquid Gold" - The unTAPped Potential of Cerebrospinal Fluid Analysis?
    Clin Cancer Res. 2020;26:2083-2084.
    PubMed     Abstract available


    April 2020
  51. RICCIUTI B, Recondo G, Spurr LF, Li YY, et al
    Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer.
    Clin Cancer Res. 2020 Apr 24. pii: 1078-0432.CCR-19-3529.
    PubMed     Abstract available


  52. COOPER AJ, Kobayashi Y, Kim D, Clifford SE, et al
    Identification of a RAS-activating TMEM87A-RASGRF1 fusion in an exceptional responder to sunitinib with non-small cell lung cancer.
    Clin Cancer Res. 2020 Apr 20. pii: 1078-0432.CCR-20-0397.
    PubMed     Abstract available


  53. PAIK PK, Kim RK, Ahn L, Plodkowski AJ, et al
    A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers.
    Clin Cancer Res. 2020;26:1796-1802.
    PubMed     Abstract available


  54. YUN MR, Kim DH, Kim SY, Joo HS, et al
    Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naive and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2020 Apr 8. pii: 1078-0432.CCR-19-2777.
    PubMed     Abstract available


  55. ZUGAZAGOITIA J, Gupta S, Liu Y, Fuhrman K, et al
    Biomarkers associated with beneficial PD-1 checkpoint blockade in non-small-cell lung cancer (NSCLC) identified using high-plex digital spatial profiling.
    Clin Cancer Res. 2020 Apr 6. pii: 1078-0432.CCR-20-0175.
    PubMed     Abstract available


  56. VAN DEN BROECK A, Brambilla E, Moro-Sibilot D, Lantuejoul S, et al
    Editor's Note: Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2020;26:1776.
    PubMed    


  57. LANDI L, Bruno R, Fontanini G, Cappuzzo F, et al
    Crizotinib in ROS1 and MET Deregulated NSCLC-Response.
    Clin Cancer Res. 2020;26:1775.
    PubMed    


  58. WIESWEG M, Schuler M, Schildhaus HU
    Crizotinib in ROS1 and MET Deregulated NSCLC-Letter.
    Clin Cancer Res. 2020;26:1774.
    PubMed    


  59. YAEGER R, Solit DB
    Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting.
    Clin Cancer Res. 2020;26:1538-1540.
    PubMed     Abstract available


    March 2020
  60. HENICK BS
    Elite Intratumoral T-cell Clonotypes (The 1%) Effect "Trickle-Down Cytotoxicity".
    Clin Cancer Res. 2020;26:1205-1207.
    PubMed     Abstract available


  61. CHUNG JS, Ramani V, Kobayashi M, Fattah F, et al
    DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors.
    Clin Cancer Res. 2020;26:1449-1459.
    PubMed     Abstract available


    February 2020
  62. ZHUO M, Guan Y, Yang X, Hong L, et al
    The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
    Clin Cancer Res. 2020;26:892-901.
    PubMed     Abstract available


  63. LIU Y, Zugazagoitia J, Ahmed FS, Henick BS, et al
    Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
    Clin Cancer Res. 2020;26:970-977.
    PubMed     Abstract available


    January 2020
  64. POCHA K, Mock A, Rapp C, Dettling S, et al
    Surfactant expression defines an inflamed subtype of lung adenocarcinoma brain metastases that correlates with prolonged survival.
    Clin Cancer Res. 2020 Jan 17. pii: 1078-0432.CCR-19-2184.
    PubMed     Abstract available


  65. DI FEDERICO A, Filippini DM, Dall'Olio FG, Conci N, et al
    The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter.
    Clin Cancer Res. 2020;26:518-519.
    PubMed    


  66. KIM BH, Kim YJ, Kim MH, Na YR, et al
    Identification of FES as a Novel Radiosensitizing Target in Human Cancers.
    Clin Cancer Res. 2020;26:265-273.
    PubMed     Abstract available


    October 2019
  67. YANG Y, Yang H, Tang B, Wu AML, et al
    The outcome of TGFbeta antagonism in metastatic breast cancer models in vivo reflects a complex balance between tumor-suppressive and pro-progression activities of TGFbeta.
    Clin Cancer Res. 2019 Oct 3. pii: 1078-0432.CCR-19-2370.
    PubMed     Abstract available


    April 2019
  68. ZHANG J, Chen J, Wo D, Yan H, et al
    LRP6 ectodomain prevents SDF-1/CXCR4-induced breast cancer metastasis to lung.
    Clin Cancer Res. 2019 Apr 22. pii: 1078-0432.CCR-18-3557.
    PubMed     Abstract available


    February 2019
  69. JEONG MH, Park SY, Lee SH, Seo J, et al
    EPB41L5 mediates TGF--induced metastasis of gastric cancer.
    Clin Cancer Res. 2019 Feb 27. pii: 1078-0432.CCR-18-2959.
    PubMed     Abstract available


  70. WANG X, Liang JQ, Zhang LH, Gou H, et al
    C8orf76 promotes gastric tumorigenicity and metastasis by directly inducing lncRNA DUSP5P1 and associates with patient outcomes.
    Clin Cancer Res. 2019 Feb 7. pii: 1078-0432.CCR-18-2804.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: